Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MARGENZA vs CLOLAR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Margetuximab is an Fc-engineered monoclonal antibody that targets the extracellular domain of human epidermal growth factor receptor 2 (HER2). It binds to HER2 on tumor cells and mediates antibody-dependent cellular cytotoxicity (ADCC) via enhanced affinity for activating Fcγ receptors (FcγRIIIa) and reduced affinity for inhibitory FcγRIIb, thereby augmenting immune effector cell activation.
Clolar (clofarabine) is a purine nucleoside antimetabolite that inhibits DNA synthesis and RNA transcription. It is phosphorylated intracellularly to its active triphosphate form, which competes with adenosine triphosphate for incorporation into DNA, leading to chain termination and inhibition of DNA polymerase and ribonucleotide reductase, resulting in apoptosis.
FDA-approved: In combination with chemotherapy (capecitabine or gemcitabine plus cisplatin) for the treatment of adults with metastatic or locally advanced unresectable HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received two or more prior anti-HER2 regimens.,Off-label: Not specified in FDA labeling; potential off-label uses may include other HER2-positive malignancies, but none are established.
FDA: Treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) in pediatric patients aged 1 to 21 years.,Off-label: Treatment of acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), chronic myeloid leukemia (CML) in blast crisis.
15 mg/kg intravenously over 60 minutes every 3 weeks until disease progression or unacceptable toxicity.
5 mg/m2 intravenously over 2 hours daily for 5 consecutive days. Repeat every 28 days.
Terminal half-life approximately 17-23 days (mean ~20 days) following intravenous administration, supporting a 3-week dosing interval for sustained receptor occupancy.
Terminal elimination half-life approximately 5.2 hours in patients with normal renal function; prolonged in renal impairment (up to 9.8 hours with Cr Cl <60 m L/min) and in elderly; clinical context: supports once-daily dosing adjustment for renal function.
Margetuximab is a monoclonal antibody; it is degraded into small peptides and amino acids via general protein catabolism. No specific metabolic enzymes or pathways are involved.
Clofarabine is partially metabolized by deamination via cytidine deaminase (CDA) to inactive 6-keto-clofarabine. Approximately 50-60% of the drug is excreted unchanged in urine.
Primarily cleared via proteolytic degradation; renal excretion of intact drug is negligible (<1%). No significant biliary or fecal elimination reported.
Renal: 50-60% as unchanged drug; biliary/fecal: minimal (<5%)
~99% bound to plasma proteins, primarily to albumin and immunoglobulin G (as a monoclonal antibody).
47% bound to human plasma proteins, primarily albumin.
Volume of distribution approximately 3.0-4.0 L (0.04-0.06 L/kg). Low Vd indicates limited extravascular distribution, consistent with large antibody molecule primarily confined to plasma and interstitial space.
Central Vd approximately 172 L/m² (extensive tissue distribution); in L/kg: ~4.6 L/kg (assuming 70 kg patient with BSA 1.73 m²). Clinical meaning: indicates wide distribution into total body water and tissues, exceeding total body water.
Bioavailability is 100% by intravenous route as it is administered as an IV infusion; not available for oral or other routes.
Intravenous: 100% (only route of administration); oral: not available (no oral formulation).
No dose adjustment recommended for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or end-stage renal disease.
Cr Cl >= 60 m L/min: no adjustment. Cr Cl 30-59 m L/min: reduce dose by 20%. Cr Cl < 30 m L/min: contraindicated.
No dose adjustment recommended for mild hepatic impairment (total bilirubin ≤ ULN and AST > ULN, or total bilirubin >1-1.5× ULN with any AST). Not studied in moderate (total bilirubin >1.5-3× ULN with any AST) or severe (total bilirubin >3× ULN with any AST) hepatic impairment.
No specific guidelines; use caution in severe hepatic impairment (Child-Pugh class C) and consider dose reduction based on tolerability.
Safety and effectiveness in pediatric patients have not been established.
1-21 years: 5 mg/m2 IV over 2 hours daily for 5 days every 28 days; reduce dose by 50% in patients with renal impairment.
No specific dose adjustment recommended. Of the 292 patients treated with MARGENZA in the SOPHIA trial, 45% were aged 65 years or older, 11% were 75 or older. No overall differences in efficacy or safety observed between elderly and younger patients.
No specific dose adjustment, but monitor renal function closely due to age-related decline and increased risk of toxicity.
No black box warning exists for MARGENZA.
WARNING: HEMATOLOGIC TOXICITY, INFECTION, AND HEPATIC TOXICITY. Clolar suppresses bone marrow function, causing severe neutropenia, thrombocytopenia, and anemia. Fatal infections have occurred. Hepatic toxicity, including hepatic failure and death, has been reported. Monitor blood counts and liver function frequently.
Cardiotoxicity: Left ventricular ejection fraction (LVEF) decline; assess LVEF prior to and during treatment. Discontinue for symptomatic heart failure or persistent decline.,Infusion-related reactions: Monitor during infusion; reduce rate or discontinue for severe reactions.,Embryo-fetal toxicity: Can cause fetal harm; advise females of reproductive potential of the risk and use effective contraception.,Pulmonary toxicity: Interstitial lung disease and pneumonitis; monitor for signs/symptoms and permanently discontinue if confirmed.,Neutropenia and febrile neutropenia: May occur; monitor blood counts.,Hypokalemia and hypomagnesemia: Monitor electrolytes and replace as needed.
Bone marrow suppression: severe neutropenia, thrombocytopenia, and anemia require close monitoring. Infections: serious and fatal infections (bacterial, fungal, viral) may occur. Hepatic toxicity: elevation of liver enzymes, bilirubin, and hepatic veno-occlusive disease. Renal toxicity: increased creatinine, hematuria, and hemolytic uremic syndrome-like reactions. Cardiac toxicity: pericardial effusion, hypotension, and ventricular dysfunction. Tumor lysis syndrome. Hypersensitivity reactions. Use in pregnancy: embryo-fetal toxicity. Vaccination: avoid live vaccines.
None known.
Absolute: Hypersensitivity to clofarabine or any component of the formulation. Relative: Severe hepatic impairment (bilirubin >3 mg/d L or transaminases >5x ULN). Severe renal impairment (creatinine clearance <30 m L/min).
No specific food interactions are known. No dietary restrictions required during treatment.
No specific food interactions are documented. However, maintain adequate hydration to reduce risk of nephrotoxicity and tumor lysis syndrome. Avoid grapefruit and grapefruit juice as they may affect metabolism via CYP3A4 (theoretical concern, though clofarabine is primarily renally excreted).
MARGENZA (margetuximab-cmkb) is an Ig G1 monoclonal antibody. Based on its mechanism of action (HER2/neu receptor blockade) and findings from animal studies with other HER2-targeted agents, it is expected to cause fetal harm or death when administered to a pregnant woman. Human Ig G molecules cross the placenta, with increasing transfer as pregnancy progresses, reaching peak levels during the third trimester. There are no adequate and well-controlled studies in pregnant women. First trimester exposure may have lower risk, but second and third trimester exposure is associated with oligohydramnios, fetal renal dysfunction, and fetal loss.
Clofarabine is contraindicated in pregnancy. Based on its mechanism of action (inhibitor of DNA synthesis) and animal studies, there is a high risk of fetal harm if administered during pregnancy. In the first trimester, there is a significant risk of embryolethality and teratogenicity (structural anomalies). In the second and third trimesters, fetal growth restriction and central nervous system damage may occur. Pregnancy must be excluded before initiation.
There are no data on the presence of margetuximab in human milk, its effects on the breastfed infant, or its effects on milk production. Maternal Ig G is present in human milk, but the amount of margetuximab transferred is expected to be low due to its large molecular size. However, because of the potential for serious adverse reactions in nursing infants, women should discontinue breastfeeding during treatment and for at least 4 months after the last dose. M/P ratio is not available.
No data available on the excretion of clofarabine into breast milk or its effects on the nursing infant. Due to potential for serious adverse reactions (e.g., myelosuppression, gastrointestinal toxicity), breastfeeding is contraindicated during therapy and for at least 3 months after the last dose. M/P ratio is unknown.
No dosage adjustment is recommended for MARGENZA based on pregnancy-induced pharmacokinetic changes; however, the drug should be avoided during pregnancy due to fetal harm. No specific pharmacokinetic studies have been conducted in pregnant women to warrant dose adjustments.
There are no established dose adjustments for clofarabine during pregnancy, as use is contraindicated. Physiological changes in pregnancy (e.g., increased plasma volume, altered renal clearance) may affect pharmacokinetics, but no dosing guidelines exist. If inadvertent exposure occurs, immediate discontinuation is recommended and the pregnancy should be managed by a maternal-fetal medicine specialist.
MARGENZA (margetuximab-cmkb) is an anti-HER2 monoclonal antibody indicated in combination with chemotherapy for metastatic HER2-positive breast cancer after two or more prior anti-HER2 regimens. Premedicate with acetaminophen, diphenhydramine, and corticosteroids to mitigate infusion-related reactions. Monitor for left ventricular ejection fraction (LVEF) decline; assess cardiac function at baseline and every 3 months during treatment. Use with caution in patients with prior anthracycline exposure or pre-existing cardiac dysfunction.
Clolar (clofarabine) is a purine nucleoside analog indicated for pediatric relapsed/refractory acute lymphoblastic leukemia. Key pearls: (1) Monitor for systemic inflammatory response syndrome (SIRS) and capillary leak syndrome; premedicate with corticosteroids. (2) Requires aggressive hydration and allopurinol for tumor lysis prophylaxis. (3) Dose reductions needed for renal impairment (Cr Cl < 60 m L/min). (4) Avoid live vaccines during and after treatment.
MARGENZA is given as an intravenous infusion every 3 weeks; each infusion takes about 90 minutes initially, then 30 minutes if well tolerated.,You may experience infusion-related reactions such as fever, chills, or nausea; you will receive premedication to reduce these.,This drug can cause heart problems; your doctor will monitor your heart function with echocardiograms regularly.,MARGENZA can cause fetal harm if used during pregnancy; use effective contraception during treatment and for 4 months after the last dose.,Do not breastfeed during treatment and for 4 months after the last dose.,Common side effects include fatigue, nausea, diarrhea, and anemia.
Clolar is a chemotherapy drug used to treat a type of leukemia in children that has not responded to other treatments.,You may experience side effects like fever, nausea, vomiting, diarrhea, and skin rashes. Report any signs of infection or unusual bleeding.,Drink plenty of fluids as directed to prevent kidney problems. You may receive IV fluids before and after treatment.,Avoid vaccinations without doctor approval, as live vaccines are not safe during treatment.,This drug can cause severe reactions including organ inflammation and fluid retention; seek immediate medical help if you have difficulty breathing, rapid weight gain, or swelling.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MARGENZA vs CLOLAR, answered by our medical review team.
MARGENZA is a Antineoplastic Agent that works by Margetuximab is an Fc-engineered monoclonal antibody that targets the extracellular domain of human epidermal growth factor receptor 2 (HER2). It binds to HER2 on tumor cells and mediates antibody-dependent cellular cytotoxicity (ADCC) via enhanced affinity for activating Fcγ receptors (FcγRIIIa) and reduced affinity for inhibitory FcγRIIb, thereby augmenting immune effector cell activation.. CLOLAR is a Antineoplastic Agent that works by Clolar (clofarabine) is a purine nucleoside antimetabolite that inhibits DNA synthesis and RNA transcription. It is phosphorylated intracellularly to its active triphosphate form, which competes with adenosine triphosphate for incorporation into DNA, leading to chain termination and inhibition of DNA polymerase and ribonucleotide reductase, resulting in apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MARGENZA and CLOLAR depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MARGENZA is: 15 mg/kg intravenously over 60 minutes every 3 weeks until disease progression or unacceptable toxicity.. The standard adult dose of CLOLAR is: 5 mg/m2 intravenously over 2 hours daily for 5 consecutive days. Repeat every 28 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MARGENZA and CLOLAR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MARGENZA is classified as Category C. MARGENZA (margetuximab-cmkb) is an IgG1 monoclonal antibody. Based on its mechanism of action (HER2/neu receptor blockade) and findings from animal studies with other HER2-targeted. CLOLAR is classified as Category C. Clofarabine is contraindicated in pregnancy. Based on its mechanism of action (inhibitor of DNA synthesis) and animal studies, there is a high risk of fetal harm if administered du. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.